Literature DB >> 3117884

Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells.

T J Brown1, M N Lioubin, H Marquardt.   

Abstract

Supernatants from activated human T lymphocytes were highly growth inhibitory for A375 human melanoma cells. Three growth inhibiting polypeptides, transforming growth factor beta 1 (TGF-beta 1), interferon-gamma (IFN-gamma), and oncostatin M, were isolated from the acid-soluble fraction of serum-free T cell-conditioned medium and purified by gel permeation chromatography and reverse-phase high performance liquid chromatography in volatile solvents at acid pH. The purification was monitored in a growth inhibition assay. The release of TGF-beta 1 biologic activity by and the purification of IFN-gamma from the medium of activated human peripheral blood T lymphocytes have been reported. We now describe the isolation of oncostatin M from the conditioned medium of activated human T cells. The concentration of oncostatin M required for half-maximal inhibition of A375 melanoma cells was approximately 4 pM when assayed in the presence of 10% fetal bovine serum. The purified oncostatin M had an apparent m.w. 28,000 and an amino-terminal sequence that was identical with the sequence of oncostatin M isolated from supernatants of macrophage-like cells. Suboptimal concentrations of TGF-beta 1 in combination with suboptimal concentrations of IFN-gamma or oncostatin M resulted in synergistic antiproliferative responses for A375 cells (1.9 and 3.1 times the expected additive responses, respectively). Combinations of oncostatin M and IFN-gamma added simultaneously to A375 cells caused an additive growth inhibitory response. These results demonstrate that oncostatin M is a novel lymphokine, and its interaction with other cytostatic polypeptide growth inhibitors may play a role in the immune regulation of tumor cell growth.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3117884

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

1.  Helicobacter pylori induces expression and secretion of oncostatin M in macrophages in vitro.

Authors:  Zaher Zeaiter; Hugo Diaz; Markus Stein; Hien Q Huynh
Journal:  Dig Dis Sci       Date:  2010-07-27       Impact factor: 3.199

Review 2.  Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways.

Authors:  Xue Bai; David E Fisher; Keith T Flaherty
Journal:  Nat Rev Clin Oncol       Date:  2019-09       Impact factor: 66.675

3.  Oncostatin m maintains the hematopoietic microenvironment and retains hematopoietic progenitors in the bone marrow.

Authors:  Ken-ichi Minehata; Masaki Takeuchi; Yoko Hirabayashi; Tohru Inoue; Peter J Donovan; Minoru Tanaka; Atsushi Miyajima
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

Review 4.  Effects of polymorphisms in gonadotropin and gonadotropin receptor genes on reproductive function.

Authors:  Livio Casarini; Elisa Pignatti; Manuela Simoni
Journal:  Rev Endocr Metab Disord       Date:  2011-12       Impact factor: 6.514

5.  Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease.

Authors:  Kathryn L Pothoven; James E Norton; Kathryn E Hulse; Lydia A Suh; Roderick G Carter; Erin Rocci; Kathleen E Harris; Stephanie Shintani-Smith; David B Conley; Rakesh K Chandra; Mark C Liu; Atsushi Kato; Nirmala Gonsalves; Leslie C Grammer; Anju T Peters; Robert C Kern; Paul J Bryce; Bruce K Tan; Robert P Schleimer
Journal:  J Allergy Clin Immunol       Date:  2015-04-01       Impact factor: 10.793

Review 6.  The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.

Authors:  Kathryn L Pothoven; Robert P Schleimer
Journal:  Tissue Barriers       Date:  2017-06-13

7.  Early differential expression of oncostatin M in obstructive nephropathy.

Authors:  Wafa M Elbjeirami; Luan D Truong; Ahmad Tawil; Wansheng Wang; Sara Dawson; Hui Y Lan; Ping Zhang; Gabriela E Garcia; C Wayne Smith
Journal:  J Interferon Cytokine Res       Date:  2010-07       Impact factor: 2.607

8.  Oncostatin M promotes bone formation independently of resorption when signaling through leukemia inhibitory factor receptor in mice.

Authors:  Emma C Walker; Narelle E McGregor; Ingrid J Poulton; Melissa Solano; Sueli Pompolo; Tania J Fernandes; Matthew J Constable; Geoff C Nicholson; Jian-Guo Zhang; Nicos A Nicola; Matthew T Gillespie; T John Martin; Natalie A Sims
Journal:  J Clin Invest       Date:  2010-01-04       Impact factor: 14.808

9.  Promoter DNA methylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer.

Authors:  Myoung Sook Kim; Joost Louwagie; Beatriz Carvalho; Jochim S Terhaar Sive Droste; Hannah Lui Park; Young Kwang Chae; Keishi Yamashita; Junwei Liu; Kimberly Laskie Ostrow; Shizhang Ling; Rafael Guerrero-Preston; Semra Demokan; Zubeyde Yalniz; Nejat Dalay; Gerrit A Meijer; Wim Van Criekinge; David Sidransky
Journal:  PLoS One       Date:  2009-08-07       Impact factor: 3.240

10.  Oncostatin m is produced in adipose tissue and is regulated in conditions of obesity and type 2 diabetes.

Authors:  David Sanchez-Infantes; Ursula A White; Carrie M Elks; Ron F Morrison; Jeffrey M Gimble; Robert V Considine; Anthony W Ferrante; Eric Ravussin; Jacqueline M Stephens
Journal:  J Clin Endocrinol Metab       Date:  2013-12-02       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.